[Spectrum and risk factors of invasive fungal infection].
In recent years, invasive fungal infection has become a growing problem in immunosuppressed patients. Simultaneously, changes in medical practice, such as the use of anti-Candida prophylaxis with azoles, has led to a shift in the epidemiology of these infections from Candida spp. to Aspergillus and other filamentous molds. Moreover, new risk factors for invasive fungal infection have been identified and the time of onset is different from that seen a decade ago. Recognition of these trends in patients receiving novel immunosuppressive regimens has important implications for the clinical management of fungal infection in this population.
Osorio
Juan José Castón
JJ
Unidad de Gestión Clínica de Enfermedades Infecciosas, Hospital Universitario Reina Sofía, Córdoba, España. juanjoco2005@yahoo.es
Román
Antonio Rivero
AR
Torre-Cisneros
Julián
J
D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D001228:Aspergillosis / Q000188:drug therapy / Q000453:epidemiology; D002648:Child; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D005260:Female; D016469:Fungemia / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000145:classification; D007223:Infant; D008297:Male; D009181:Mycoses / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D020096:Zygomycosis / Q000188:drug therapy / Q000453:epidemiology
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents